e-learning
resources
Vienna 2009
Monday, 14.09.2009
New bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD
H. K. Yum, I. N. Park, S. B. Choi, H. K. Kim, H. Jung, J. W. Hur, H. K. Lee, S. S. Lee, H. P. Lee, S. J. Choi (Seoul, Busan, Ilsan, Republic Of Korea)
Source:
Annual Congress 2009 - New bronchodilators
Session:
New bronchodilators
Session type:
Thematic Poster Session
Number:
2033
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. K. Yum, I. N. Park, S. B. Choi, H. K. Kim, H. Jung, J. W. Hur, H. K. Lee, S. S. Lee, H. P. Lee, S. J. Choi (Seoul, Busan, Ilsan, Republic Of Korea). Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD. Eur Respir J 2009; 34: Suppl. 53, 2033
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 14s
Year: 2005
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD
Source: Eur Respir J 2013; 42: 539-541
Year: 2013
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Bronchodilator efficacy of tiotropium in patients with mild COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006
Rational timing of combination therapy with tiotropium and formoterol in moderate-severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 214s
Year: 2006
Comparative effects of formoterol monotherapy versus formoterol
plus
tiotropium on dynamic hyperinflation and exercise tolerance in COPD
Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance
Year: 2009
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler
Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Year: 2012
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Source: International Congress 2018 – COPD management
Year: 2018
Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe COPD in France
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Safety and tolerability of high-dose formoterol
via
aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept